Antitumor Immunity Exerted by Natural Killer and Natural Killer T Cells in the Liver.
NK cells
NKT cells
innate immunity
tumor immunity
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Jan 2023
21 Jan 2023
Historique:
received:
22
11
2022
revised:
10
01
2023
accepted:
19
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
The liver plays crucial roles in systemic immunity and greatly contributes to the systemic defense mechanism. Antitumor immunity in the liver is especially critical for the defense against systemic tumor cell dissemination. To achieve effective defense against metastatic tumor cells, liver immune cells with powerful cytotoxic activities construct a potent defense mechanism. In the liver, as compared with other organs, there is a significantly more intense percentage of innate immune lymphocytes, such as natural killer (NK) and NKT cells. These characteristic lymphocytes survey the portal blood transferred to the liver from the alimentary tract and eliminate malignant cells with their robust cytotoxic ability. Additionally, with their active cytokine-producing capacity, these innate lymphocytes initiate immunological sequences by adaptive immune cells. Therefore, they are crucial contributors to systemic antitumor immunity. These attractive immune cells help conduct a fundamental investigation of tumor immunity and act as a target of clinical measures for cancer therapies. This review discusses the mechanisms of these innate lymphocytes regarding recognition and cytotoxicity against tumor cells and the possibility of clinical applications for therapeutic measures.
Identifiants
pubmed: 36769513
pii: jcm12030866
doi: 10.3390/jcm12030866
pmc: PMC9917438
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K07438
Références
J Clin Invest. 2016 Jun 1;126(6):2341-55
pubmed: 27183388
Eur J Immunol. 2014 Nov;44(11):3368-79
pubmed: 25100508
J Exp Med. 1998 Dec 21;188(12):2375-80
pubmed: 9858524
Immunol Today. 1990 Jul;11(7):237-44
pubmed: 2201309
J Immunol. 1994 Jul 15;153(2):637-46
pubmed: 8021501
Science. 2020 May 29;368(6494):
pubmed: 32299851
J Clin Invest. 2014 Nov;124(11):4781-94
pubmed: 25329698
Cancer Cell. 2018 Oct 8;34(4):596-610.e11
pubmed: 30300581
Nature. 2020 Mar;579(7799):415-420
pubmed: 32188940
Oncoimmunology. 2018 Feb 12;7(6):e1428156
pubmed: 29872551
J Exp Med. 1994 Sep 1;180(3):1097-106
pubmed: 7520467
Cancer Immunol Immunother. 2008 Mar;57(3):337-45
pubmed: 17690880
Int J Cancer. 1975 Aug 15;16(2):230-9
pubmed: 1080480
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Clin Cancer Res. 2000 Aug;6(8):3380-7
pubmed: 10955826
Science. 1991 Jul 12;253(5016):199-202
pubmed: 1853205
Cancer Res. 1999 Oct 15;59(20):5102-5
pubmed: 10537282
Blood. 2013 Jan 17;121(3):423-30
pubmed: 23100308
Int J Cancer. 2005 Aug 10;116(1):87-93
pubmed: 15756674
J Exp Med. 2009 Feb 16;206(2):287-98
pubmed: 19171762
Int J Immunopharmacol. 1999 Jan;21(1):1-14
pubmed: 10411278
Front Oncol. 2020 Aug 26;10:1594
pubmed: 32984022
J Hepatol. 2005 Oct;43(4):670-8
pubmed: 15922476
J Immunol. 2005 Apr 15;174(8):4696-705
pubmed: 15814694
Clin Cancer Res. 2002 Dec;8(12):3702-9
pubmed: 12473579
Cancer Immunol Res. 2017 Aug;5(8):642-653
pubmed: 28637878
J Immunol. 1990 Nov 15;145(10):3209-15
pubmed: 1977798
Nat Rev Immunol. 2015 Jun;15(6):388-400
pubmed: 25998963
J Immunol. 2001 Sep 15;167(6):3114-22
pubmed: 11544296
Nat Rev Immunol. 2006 Aug;6(8):595-601
pubmed: 16868550
Annu Rev Immunol. 2005;23:225-74
pubmed: 15771571
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5690-3
pubmed: 9576945
Nature. 1994 Dec 15;372(6507):691-4
pubmed: 7527500
Elife. 2015 Nov 13;4:
pubmed: 26565589
PLoS One. 2011;6(6):e20702
pubmed: 21695190
Nature. 2012 Mar 25;484(7395):529-33
pubmed: 22446627
Nat Immunol. 2002 Sep;3(9):867-74
pubmed: 12154358
Int Rev Immunol. 1994;11(1):31-46
pubmed: 8057043
Nature. 2005 Aug 25;436(7054):1186-90
pubmed: 15995699
Eur J Immunol. 1993 Jan;23(1):307-10
pubmed: 8419184
J Immunol. 2002 Dec 1;169(11):6127-32
pubmed: 12444115
J Immunol. 1991 Aug 15;147(4):1214-21
pubmed: 1831220
J Immunol. 1991 Feb 15;146(4):1113-7
pubmed: 1825103
J Immunol. 2001 Oct 1;167(7):4046-50
pubmed: 11564825
J Leukoc Biol. 2012 Feb;91(2):299-309
pubmed: 22045868
J Immunol. 2002 Jun 15;168(12):6494-9
pubmed: 12055270
J Immunol. 2001 Jun 1;166(11):6578-84
pubmed: 11359810
Clin Cancer Res. 2019 Dec 1;25(23):7126-7138
pubmed: 31484667
Int Immunol. 1995 Jul;7(7):1157-61
pubmed: 8527413
Immunology. 2001 Jul;103(3):281-90
pubmed: 11454057
Leuk Res. 2005 Feb;29(2):147-52
pubmed: 15607362
N Engl J Med. 1987 Apr 9;316(15):889-97
pubmed: 3493432
Nat Rev Immunol. 2004 Mar;4(3):231-7
pubmed: 15039760
Annu Rev Immunol. 2013;31:413-41
pubmed: 23298206
Science. 1995 May 12;268(5212):863-5
pubmed: 7538697
Hepatology. 2000 Nov;32(5):962-9
pubmed: 11050046
Annu Rev Immunol. 1996;14:207-32
pubmed: 8717513
J Immunol. 2004 Jun 1;172(11):6550-7
pubmed: 15153469
Immunol Rev. 2007 Dec;220:169-82
pubmed: 17979846
Cell Immunol. 1990 Sep;129(2):478-93
pubmed: 2143439
J Exp Med. 1990 Jul 1;172(1):7-12
pubmed: 2141631
Cancers (Basel). 2021 Oct 15;13(20):
pubmed: 34680322
J Immunol. 1995 Sep 15;155(6):2972-83
pubmed: 7673715
Science. 1997 Nov 28;278(5343):1626-9
pubmed: 9374463